SL Science

SL Science (Nasdaq: SLBT) is scaling the future of cell therapy through its GDT (γδ T Cell) platform, making innovative immunotherapy more accessible worldwide.

[SL Science @SLScience_SLBT]

Exosomes can cross the blood-brain barrier where whole cells can't, and preclinical data shows they trigger tumor cell death + work synergistically with radiotherapy.

👉 Read the full press release: https://t.co/8xcDMG4A2z

[SL Science @SLScience_SLBT]

New FDA DMF #044612 covers our GDT-derived exosomes — now both the cells and exosomes each have their own registered filing.

#SLScience #SLBT

[SL Science @SLScience_SLBT]

We remain focused on advancing our Gamma Delta (γδ) T cell platform across scientific, academic, and regulatory fronts — exploring its potential as a complementary approach to cancer treatment.

👉 Read the full press release: https://t.co/VQje7wa1IR

[SL Science @SLScience_SLBT]

🔔 Today, SL Science leadership rang the Closing Bell at Nasdaq MarketSite in New York, marking our first appearance at Nasdaq since our listing on June 15, 2026.

#SLScience #SLBT #GammaDeltaT #CellTherapy

[SL Science @SLScience_SLBT]

🎥 Watch our Nasdaq Closing Bell Ringing Ceremony live here:
https://t.co/MlLcw80t1k

[SL Science @SLScience_SLBT]

We're heading to Nasdaq! 🔔

SL Science (Nasdaq: SLBT) celebrates our Closing Bell Ceremony at Nasdaq MarketSite, NYC on Sept 2, 2026 (ET). Can't join in person?

Tune in to our livestream — link coming soon.

#SLScience #NasdaqListed #SLBT

[SL Science @SLScience_SLBT]

📚 References:
¹ Cancer Research, Statistics, and Treatment (2024)
² Frontiers in Immunology (2025)
³ MDPI Cancers (2026)
⁴ MDPI Future Pharmacology (2025)
⁵ MDPI Cancers (2024)

[SL Science @SLScience_SLBT]

30 years. Major trials. Billions invested. Glioblastoma survival rates have barely moved.
Three structural barriers have defeated every therapy thrown at it:
🔴 GBM engineers its own immune shield
🔴 Blood-brain barrier blocks most drugs
🔴 Tumor heterogeneity drives resistance

[SL Science @SLScience_SLBT]

Conventional therapies were built around immune recognition pathways that GBM has evolved to neutralize.

Our GDT platform addresses all three at the mechanistic level — and these preclinical findings are building the scientific foundation for what comes next.

#Glioblastoma #GDT

[SL Science @SLScience_SLBT]

✓ Broad stress-signal recognition
✓ Off-the-shelf manufacturing potential
✓ Clear roadmap for future trials

👉 Read the full press release: https://t.co/s8V7IgXYm3

[SL Science @SLScience_SLBT]

New peer-reviewed paper:
SL Science leadership + Taipei Medical University clinical researchers outline a rigorous development framework for γδ T cell therapy in glioblastoma.

📄 Full paper: https://t.co/2HAWn6hgFQ

#SLScience #Glioblastoma #CellTherapy

[SL Science @SLScience_SLBT]

📚 References:
¹ Egyptian Journal of Neurosurgery (2024)
https://t.co/5fVi0jdvQm
² Frontiers in Immunology (2025)
https://t.co/6lrmxQ3tAa
³ MDPI Cancers (2025)
https://t.co/D9OHYw96SD
⁴ MDPI Cancers (2023)
https://t.co/woCAQumaxC

[SL Science @SLScience_SLBT]

🧠 Why does immunotherapy work wonders in most cancers, but barely touch glioblastoma?

GBM — median survival 15 months¹ — actively blinds immune cells before they can attack.² Conventional therapies depend on recognition pathways GBM can simply turn off.³

[SL Science @SLScience_SLBT]

γδ T cells (GDT) bypass GBM's defenses by detecting stress signals tumors can't hide — no MHC recognition required.⁴

These preclinical findings are building the scientific foundation for what comes next.

[SL Science @SLScience_SLBT]

"This research underscores the tremendous therapeutic potential of our γδ T-cell platform to combat challenging solid tumors like glioblastoma." — William Wang, Chairman & CEO

#WorldBrainDay #WCP2026 #Glioblastoma #CellTherapy

[SL Science @SLScience_SLBT]

🧠 WorldBrainDay 2026: "Brain Health: Access for All"

3.4 billion people live with neurological conditions. Glioblastoma — one of the deadliest brain tumors — remains unsolved.

Last week at #WCP2026 Melbourne, we took a step forward.

🔗 See More: https://t.co/QYpemYu6Ns

[SL Science @SLScience_SLBT]

$SLBT + Taipei Medical University, JY BioMed & HeXun Biosciences presented preclinical γδ T-cell data:

✅ Complete tumor eradication by Day 26
✅ Dose-dependent suppression
✅ Clean safety profile

[SL Science @SLScience_SLBT]

Read JY BioMed's full article ⬇️
https://t.co/4WKlqdACqs

[SL Science @SLScience_SLBT]

We're proud to share that our CTO, Dr. Ethan Shen, attended WCP2026 Melbourne alongside JY BioMed's CMO, Dr. Bo-Xiang Zhang — as GDT platform preclinical findings took the world stage, with tumor signal dropping to undetectable levels in the highest-dose glioblastoma model.

[JY BioMed @JY_BioMed]

Taiwan biotech breakthrough 🧬

JY BioMed's γδ T cell therapy, developed with Taipei Medical University, showed complete tumor signal disappearance in the highest-dose group in a brain cancer (GBM) model.

[SL Science @SLScience_SLBT]

A meaningful milestone for the GDT platform's global journey.

#SLBT #GDT #BrainCancer #GBM #WCP2026 #Biotech